Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av Lasofoxifen kombinert med Abemaciclib sammenlignet med Fulvestrant kombinert med Abemaciclib ved lokalt avansert eller metastatisk ER+/HER2- Brystkreft med en ESR1-mutasjon (ELAINEIII)

10. november 2026 oppdatert av: LeonaBio

En åpen etikett, randomisert, multisenterstudie som sammenligner effektiviteten og sikkerheten til kombinasjonen av Lasofoxifen og Abemaciclib med kombinasjonen av Fulvestrant og Abemaciclib for behandling av pre- og postmenopausale kvinner og menn med lokalt avansert eller metastatisk ER+/HER2- brystkreft med en ESR1-mutasjon

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

600

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Simon Daggett - Senior Vice President, Clinical Operations
  • Telefonnummer: (425) 620-8772 (909) 374-3793
  • E-post: clinicaltrials@leonabio.com

Studiesteder

      • Blacktown, Australia
      • Concord, Australia
      • South Brisbane, Australia
        • Rekruttering
        • Mater Misericordiae Ltd, South Brisbane
        • Ta kontakt med:
    • Ontario
      • Ottawa, Ontario, Canada
        • Rekruttering
        • The Ottawa General Hospital
        • Ta kontakt med:
      • Toronto, Ontario, Canada
        • Rekruttering
        • Sunnybrook Health Sciences Centre -Bayview Campus
        • Ta kontakt med:
    • Quebec
      • Montreal, Quebec, Canada
        • Rekruttering
        • Lady Davis Institute for Medical Research Jewish General Hospital
        • Ta kontakt med:
      • Montreal, Quebec, Canada
      • Saguenay, Quebec, Canada
        • Tilbaketrukket
        • CIUSSS du Saguenay-Lac-Saint-Jean
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85259
        • Rekruttering
        • Mayo Clinic - Scottsdale
        • Ta kontakt med:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
      • Tucson, Arizona, Forente stater, 85719
        • Rekruttering
        • University of Arizona - Cancer Center
        • Ta kontakt med:
    • California
      • Santa Rosa, California, Forente stater, 95403
        • Rekruttering
        • Providence Medical Foundation - Santa Rosa, CA
        • Ta kontakt med:
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Mayo Clinic - Jacksonville
        • Ta kontakt med:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
      • Miami, Florida, Forente stater, 33143
      • Plantation, Florida, Forente stater, 33324
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
    • Kentucky
    • Maryland
      • Baltimore, Maryland, Forente stater, 21231
        • Rekruttering
        • Johns Hopkins Kimmel Cancer Center
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
      • Boston, Massachusetts, Forente stater, 02215
        • Fullført
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forente stater, 02115
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49503
        • Rekruttering
        • Cancer and Hematology Centers of Western Michigan
        • Ta kontakt med:
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55407
        • Fullført
        • Allina Health System DBA Virginia Piper Cancer Institute
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic - Rochester
        • Ta kontakt med:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • Rekruttering
        • Saint Luke's Cancer Institute
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Ta kontakt med:
    • Nevada
      • Reno, Nevada, Forente stater, 89502
      • Reno, Nevada, Forente stater, 89511-2250
        • Rekruttering
        • Cancer Care Specialists
        • Ta kontakt med:
    • New Jersey
      • Belleville, New Jersey, Forente stater, 07109
        • Tilbaketrukket
        • New Jersey Cancer Care, PA
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
        • Ta kontakt med:
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87110
        • Har ikke rekruttert ennå
        • Presbyterian Kaseman Hospital
        • Ta kontakt med:
      • Rio Rancho, New Mexico, Forente stater, 87124
        • Rekruttering
        • Presbyterian Rust Cancer Center
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
        • Ta kontakt med:
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Ta kontakt med:
      • New York, New York, Forente stater, 10011
        • Rekruttering
        • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Ta kontakt med:
    • North Dakota
      • Grand Forks, North Dakota, Forente stater, 58201
        • Fullført
        • Altru Health Systems
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
      • Cleveland, Ohio, Forente stater, 44119
        • Tilbaketrukket
        • Cleveland Clinic
      • Columbus, Ohio, Forente stater, 42112
        • Rekruttering
        • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Fullført
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, Forente stater, 77030
      • Houston, Texas, Forente stater, 77030
      • Houston, Texas, Forente stater, 77054
        • Rekruttering
        • Harris Health System - Smith Clinic
        • Hovedetterforsker:
          • Ahmed Elkhanany
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Tilbaketrukket
        • Swedish Cancer Institute (SCI)
      • Afula, Israel, 1834111
      • Beersheba, Israel, 8486614
      • Haifa, Israel
      • Jerusalem, Israel
      • Jerusalem, Israel
        • Rekruttering
        • Hadassah Ein-Karem Medical Center
        • Ta kontakt med:
      • Kfar Saba, Israel, 4428164
      • Petah Tikva, Israel
      • Rehovot, Israel
        • Rekruttering
        • Kaplan Medical Center
        • Ta kontakt med:
      • Tel Aviv, Israel
        • Rekruttering
        • Tel Aviv Sourasky Medical Center
        • Ta kontakt med:
      • Tel HaShomer, Israel
      • Ancona, Italia
      • Aviano, Italia
      • Candiolo, Italia, 10060
        • Rekruttering
        • La Fondazione e l'Istituto di Candiolo
        • Ta kontakt med:
      • Meldola, Italia
        • Rekruttering
        • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
        • Ta kontakt med:
      • Milan, Italia
      • Misterbianco, Italia
        • Rekruttering
        • Humanitas Istituto Clinico Catanese
        • Ta kontakt med:
      • Modena, Italia
        • Rekruttering
        • Azienda Ospedaliero-Universitaria di Modena
        • Ta kontakt med:
      • Naples, Italia
      • Novara, Italia, 28100
        • Tilbaketrukket
        • Azienda Ospedaliero Universitaria Maggiore Della Carita
      • Padova, Italia, 35128
        • Rekruttering
        • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
        • Ta kontakt med:
      • Parma, Italia
      • Pavia, Italia
        • Rekruttering
        • Fondazione IRCCS Policlinico San Matteo
        • Hovedetterforsker:
          • Gianpiero Rizzo
        • Ta kontakt med:
      • Roma, Italia
      • Verona, Italia
        • Fullført
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Anhui, Kina
        • Rekruttering
        • Anhui Provincial Cancer Hospital
        • Ta kontakt med:
      • Anyang, Kina
      • Beijing, Kina
        • Rekruttering
        • Peking Union Medical College Hospital
        • Ta kontakt med:
      • Beijing, Kina
        • Rekruttering
        • Beijing Cancer Hospital
        • Ta kontakt med:
      • Bengbu, Kina
        • Rekruttering
        • The First Affiliated Hospital of Bengbu Medical University
        • Ta kontakt med:
      • Changchun, Kina
        • Rekruttering
        • The First Hospital of Jilin University
        • Ta kontakt med:
      • Changsha, Kina
        • Rekruttering
        • The Second Xiangya Hospital of Central South University
        • Ta kontakt med:
      • Chengdu, Kina
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Ta kontakt med:
      • Chengdu, Kina
        • Rekruttering
        • West China Hospital, Sichuan University
        • Ta kontakt med:
      • Chongqicun, Kina
        • Rekruttering
        • The First Affiliated Hospital, Chongqing Medical University
        • Ta kontakt med:
      • Dalian, Kina
        • Rekruttering
        • The Second Hospital of Dalian Medical University
        • Ta kontakt med:
      • Deyang, Kina
        • Rekruttering
        • Deyang People's Hospital
        • Ta kontakt med:
      • Fuyang, Kina
        • Rekruttering
        • Fuyang Cancer Hosptial
        • Ta kontakt med:
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Cancer Hospital
        • Ta kontakt med:
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Ta kontakt med:
      • Guandong, Kina
        • Rekruttering
        • Zhujiang Hospital of Nanfang Medical University
        • Ta kontakt med:
      • Guangdong, Kina
        • Rekruttering
        • Guangdong Provincial People's Hospital
        • Ta kontakt med:
      • Guangdong, Kina
        • Rekruttering
        • Meizhou People's Hospital
        • Ta kontakt med:
      • Guangdong, Kina
        • Rekruttering
        • Peking University Shenzhen Hospital
        • Ta kontakt med:
          • Xiaoling Liu
      • Guangdong, Kina
        • Rekruttering
        • Sun Yat-Sen University- Cancer Center
        • Ta kontakt med:
      • Guangzhou, Kina
        • Rekruttering
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Ta kontakt med:
      • Haikou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Hainan Medical University
        • Ta kontakt med:
      • Hangzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
        • Ta kontakt med:
      • Hangzhou, Kina
        • Rekruttering
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Ta kontakt med:
      • Hangzhou, Kina
        • Rekruttering
        • Zhejiang Provincial Hospital of Chinese Medicine
        • Ta kontakt med:
      • Hebei, Kina
        • Rekruttering
        • Hebei Medical University - The Fourth Hospital - Hebei Provincial Tumor Hospital
        • Ta kontakt med:
      • Hubei, Kina
        • Rekruttering
        • Xiangyang Central Hospital
        • Ta kontakt med:
      • Hunan, Kina
        • Rekruttering
        • Xiangya Hospital Central South University
        • Ta kontakt med:
      • Jieyang, Kina
        • Rekruttering
        • Jieyang People's Hospital
        • Ta kontakt med:
      • Jinan, Kina
        • Rekruttering
        • Shandong Province Tumor Hospital
        • Ta kontakt med:
      • Kunming, Kina
        • Rekruttering
        • Yunnan Cancer Hospital
        • Ta kontakt med:
      • Lanzhou, Kina
        • Rekruttering
        • The First Hospital of Lanzhou University
        • Ta kontakt med:
      • Lanzhou, Kina
        • Rekruttering
        • Gansu Provincial Hospital
        • Ta kontakt med:
      • Linyi, Kina
        • Rekruttering
        • Linyi Cancer Hospital
        • Ta kontakt med:
      • Luoyang, Kina
        • Rekruttering
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Ta kontakt med:
      • Luoyang, Kina
        • Rekruttering
        • Luoyang Central Hospital
        • Ta kontakt med:
      • Luzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Southwest Medical University (Luzhou Medical College)
        • Ta kontakt med:
      • Nanchang, Kina
        • Rekruttering
        • Jiangxi Cancer Hospital
        • Ta kontakt med:
      • Nanchang, Kina
        • Rekruttering
        • Nanchang People's Hospital
        • Ta kontakt med:
      • Nanjing, Kina
        • Rekruttering
        • Nanjing Drum Tower Hospital
        • Ta kontakt med:
      • Nanjing, Kina
        • Rekruttering
        • Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University
        • Ta kontakt med:
      • Nanning, Kina
        • Rekruttering
        • Guangxi Medical University Cancer Hospital
        • Ta kontakt med:
      • Nanyang, Kina
        • Rekruttering
        • Nanyang Central Hospital
        • Ta kontakt med:
      • Neijiang, Kina
        • Rekruttering
        • The Second People's Hospital of Neijiang
        • Ta kontakt med:
      • Ningbo, Kina
        • Rekruttering
        • Ningbo Medical Center Li Huili Hospital
        • Ta kontakt med:
      • Pingdingshan, Kina
        • Rekruttering
        • The First People'S Hospital of Ping Ding Shan
        • Ta kontakt med:
      • Qingdao, Kina
        • Rekruttering
        • The Affiliated Hospital of Qingdao University
        • Ta kontakt med:
      • Qingdao, Kina
        • Rekruttering
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Ta kontakt med:
      • Quanzhou, Kina
        • Rekruttering
        • Quanzhou First Hospital
        • Ta kontakt med:
      • Shanghai, Kina
        • Rekruttering
        • Huashan Hospital, Fudan University
        • Ta kontakt med:
      • Shanghai, Kina
        • Rekruttering
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Ta kontakt med:
      • Shang’ai, Kina
        • Rekruttering
        • Fudan University Cancer Center
        • Ta kontakt med:
      • Shanxi, Kina
        • Rekruttering
        • First Affiliated Hospital of Xi'an Jiaotong University
        • Ta kontakt med:
      • Shaoyang, Kina
        • Rekruttering
        • The Central Hospital of Shaoyang
        • Ta kontakt med:
      • Shenyang, Kina
        • Rekruttering
        • Liaoning Cancer Hospital & Institute
        • Ta kontakt med:
      • Shouguang, Kina
        • Rekruttering
        • Yuebei People's Hospital
        • Ta kontakt med:
      • Sichuan, Kina
        • Rekruttering
        • University of Electonic Science & Technology (UESTC) - Sichuan Cancer Hospital & Institute
        • Ta kontakt med:
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Medical University Cancer Institute & Hospital
        • Ta kontakt med:
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Cancer Hospital Airport Hospital
        • Ta kontakt med:
      • Wenzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Wenzhou Medical University
        • Ta kontakt med:
      • Wuhan, Kina
        • Rekruttering
        • Hubei Cancer Hospital
        • Ta kontakt med:
      • Wuhan, Kina
        • Rekruttering
        • Union Hospital Tongji Medical College Huazhong University of Science and Technolog
        • Ta kontakt med:
      • Wuhu, Kina
        • Rekruttering
        • The Second People's Hospital of WuHu
        • Ta kontakt med:
      • Xi Ail, Kina
        • Rekruttering
        • The First Affiliated Hospital of Air Force Medical University
        • Ta kontakt med:
      • Xiamen, Kina
        • Rekruttering
        • Zhongshang Hospital Xiamen University
        • Ta kontakt med:
      • Xiamen, Kina
        • Rekruttering
        • The first affiliated hospital of Xiamen University
        • Ta kontakt med:
      • Xinzheng, Kina
        • Rekruttering
        • The Second Affiliated Hospital Of Xi'an Jiaotong University
        • Ta kontakt med:
      • Xuzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Xuzhou Medical University
        • Ta kontakt med:
      • Xuzhou, Kina
        • Rekruttering
        • Xuzhou Central Hospital
        • Ta kontakt med:
      • Yuncheng, Kina
        • Rekruttering
        • Yuncheng Central Hospital
        • Ta kontakt med:
      • Zhejiang, Kina
        • Rekruttering
        • Zhejiang Provincial People's Hospital
        • Ta kontakt med:
      • Zhejiang, Kina
        • Rekruttering
        • Zhejiang cancer hospital
        • Ta kontakt med:
      • Zhengzhou, Kina
        • Rekruttering
        • Henan Cancer Hospital
        • Ta kontakt med:
      • Zhengzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
      • Zhongshan, Kina
        • Rekruttering
        • Zhongshan City People's Hospital
        • Ta kontakt med:
      • Zhumadian, Kina
        • Rekruttering
        • Zhumadian Central Hospital
        • Ta kontakt med:
      • Ürümqi, Kina
        • Rekruttering
        • The Affiliated Cancer Hospital of Xinjiang Medical University
        • Ta kontakt med:
      • Biała Podlaska, Polen
        • Tilbaketrukket
        • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gliwice, Polen
        • Tilbaketrukket
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
      • Krakow, Polen
        • Rekruttering
        • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
        • Ta kontakt med:
      • Krakow, Polen
      • Lodz, Polen
        • Fullført
        • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
      • Poznan, Polen
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
        • Ta kontakt med:
      • Poznan, Polen
        • Rekruttering
        • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
        • Ta kontakt med:
      • Wieliszew, Polen
        • Rekruttering
        • Mazowiecki Szpital Onkologiczny
        • Ta kontakt med:
      • Bucharest, Romania
        • Rekruttering
        • Memorial Healthcare International SRL
        • Ta kontakt med:
      • Bucharest, Romania
        • Tilbaketrukket
        • Centrul Medical Focus
      • Cluj-Napoca, Romania
      • Craiova, Romania
        • Rekruttering
        • Oncology Center Sfantul Nectarie
        • Ta kontakt med:
      • Craiova, Romania
        • Fullført
        • Onco Clinic Consult SA
      • Piteşti, Romania
        • Rekruttering
        • Gral Medical SRL
        • Ta kontakt med:
      • Timișoara, Romania
        • Rekruttering
        • OncoMed Oncology Center
        • Ta kontakt med:
      • Singapore, Singapore, 329563
      • Barcelona, Spania
        • Rekruttering
        • Hospital Universitario Vall d'Hebron
        • Ta kontakt med:
      • Barcelona, Spania
      • Córdoba, Spania
        • Rekruttering
        • Hospital Universitario Reina Sofia
        • Ta kontakt med:
      • Madrid, Spania, 28034
        • Rekruttering
        • Hospital Universitario Ramon y Cajal
        • Ta kontakt med:
      • Madrid, Spania, 28040
      • Madrid, Spania
        • Rekruttering
        • Hospital Universitario 12 de Octubre
        • Ta kontakt med:
      • Madrid, Spania
      • Madrid, Spania
        • Rekruttering
        • Clinica Universidad de Navarra - Madrid
        • Ta kontakt med:
      • Madrid, Spania
        • Rekruttering
        • Hospital Beata Maria Ana
        • Ta kontakt med:
      • Madrid, Spania
        • Rekruttering
        • Hospital General Universitario Gregorio Maranon
        • Ta kontakt med:
      • Málaga, Spania
      • Pamplona, Spania
        • Rekruttering
        • Clinica Universidad de Navarra - Pamplona
        • Ta kontakt med:
      • Valencia, Spania
        • Rekruttering
        • Instituto Valenciano de Oncologia
        • Ta kontakt med:
      • Cardiff, Storbritannia, CF14 2TL
      • Harlow, Storbritannia, CM20 1QX
        • Rekruttering
        • Princess Alexandra Hospital - Harlow
        • Ta kontakt med:
      • Leeds, Storbritannia
      • London, Storbritannia
        • Rekruttering
        • Charing Cross Hospital
        • Ta kontakt med:
      • London, Storbritannia, NW3 2
        • Rekruttering
        • Royal Free London NHS Foundation Trust
        • Ta kontakt med:
      • Manchester, Storbritannia
      • Milton Keynes, Storbritannia, MK6 5LD
      • Nottingham, Storbritannia
      • Stockton-on-Tees, Storbritannia, TS198PE
        • Tilbaketrukket
        • University Hospital of North Tees
      • Gyeonggi-do, Sør -Korea
        • Rekruttering
        • National Cancer Center
        • Ta kontakt med:
      • Jeollanam-do, Sør -Korea, 58128
        • Rekruttering
        • Chonnam National University Hwasun Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Korea University Anam Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Tilbaketrukket
        • Severance Hospital, Yonsei University Health System
      • Seoul, Sør -Korea
        • Tilbaketrukket
        • Asan Medical Center
      • Changhua, Taiwan
        • Rekruttering
        • Changhua Christian Hospital (CCH)
        • Ta kontakt med:
      • Kaohsiung City, Taiwan
        • Rekruttering
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
        • Ta kontakt med:
      • Tainan, Taiwan
        • Rekruttering
        • National Cheng Kung University Hospital
        • Ta kontakt med:
      • Taipei, Taiwan
        • Rekruttering
        • National Taiwan University Hospital
        • Ta kontakt med:
      • Taipei, Taiwan
        • Rekruttering
        • Tri-Service General Hospital
        • Ta kontakt med:
      • Taipei, Taiwan
        • Rekruttering
        • Koo Foundation Sun Yat-Sen Cancer Center
        • Ta kontakt med:
      • Taoyuan City, Taiwan
        • Rekruttering
        • Linkou Chang Gung Memorial Hospital (CGMHLK)
        • Ta kontakt med:
      • Ankara, Tyrkia (Türkiye)
        • Rekruttering
        • Ankara University Medical Faculty Medical Oncology Department
        • Ta kontakt med:
      • Bursa, Tyrkia (Türkiye)
        • Rekruttering
        • Uludag University Faculty of Medicine Hospital
        • Ta kontakt med:
      • Edirne, Tyrkia (Türkiye)
      • Izmir, Tyrkia (Türkiye)
    • Ankara
      • Çankaya, Ankara, Tyrkia (Türkiye)
        • Rekruttering
        • Liv Hospital Ankara
        • Ta kontakt med:
    • Istanbul
      • Kadiköy, Istanbul, Tyrkia (Türkiye)
        • Rekruttering
        • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
        • Ta kontakt med:
      • Çapa, Istanbul, Tyrkia (Türkiye)
        • Rekruttering
        • Istanbul University CAPA Medical Faculty
        • Ta kontakt med:
    • Kocaeli
    • İzmir
      • Bornova, İzmir, Tyrkia (Türkiye)
        • Rekruttering
        • Ege University Medical Faculty Hospital
        • Ta kontakt med:
      • Konak, İzmir, Tyrkia (Türkiye)
        • Rekruttering
        • Suat Seren Training and Research Hospital
        • Ta kontakt med:
      • Dresden, Tyskland
      • München, Tyskland
        • Rekruttering
        • Klinikum rechts der Isar der Technischen Universitaet Muenchen
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Pre- or postmenopausal women or men.

  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.

  3. Histological or cytological confirmation of ER+/HER2 - disease

  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.

  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.

  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.

  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

  9. Adequate organ function

  10. Able to swallow tablets

  11. Brain metastases are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring steroids up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written informed consent before any screening procedures.

  13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Aktiv komparator: Reference Therapy

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression free survival (PFS)
Tidsramme: Within approximately 3 years

PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

Within approximately 3 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective response rate (ORR)
Tidsramme: Within approximately 3 years

ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

Within approximately 3 years
Overall survival (OS)
Tidsramme: Within approximately 3 years

Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

Within approximately 3 years
Clinical benefit rate (CBR)
Tidsramme: Within approximately 3 years

CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

Within approximately 3 years
Duration of response (DoR) in subjects with an objective response
Tidsramme: Within approximately 3 years

DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

Within approximately 3 years
Time to response (TTR) in subjects with an objective response
Tidsramme: Within approximately 3 years

TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

Within approximately 3 years
Time to cytotoxic chemotherapy
Tidsramme: Within approximately 3 years

From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

Within approximately 3 years
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Tidsramme: Within approximately 3 years

Scale ranges from 'Not at all' to 'Very much'

Within approximately 3 years
Incidence of Adverse Events (AEs) and Serious AEs
Tidsramme: Within approximately 3 years

The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Within approximately 3 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. oktober 2023

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. april 2028

Datoer for studieregistrering

Først innsendt

13. januar 2023

Først innsendt som oppfylte QC-kriteriene

13. januar 2023

Først lagt ut (Faktiske)

25. januar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere